Sinuva™
Drug - Sinuva™ (mometasone furoate implant) [Intersect ENT, Inc.]
April 2019
Therapeutic Area - Nasal polyps
Approval criteria
- Patients is ≥ 18 years of age AND
- Patient has a diagnosis of recurrent nasal polyps and chronic sinusitis (e.g., nasal obstruction/congestion, post-nasal discharge, thick nasal discharge, facial pain/pressure, or decreased sense of smell) and recurrent bilateral sinus obstruction AND
- Patient has nasal obstruction/congestion score of ≥ 2 despite use of two preferred intranasal corticosteroids AND
- Patient has undergone ethmoid sinus surgery > 90 days prior to implantation AND
- Patient does not have a known hypersensitivity to mometasone furoate or any ingredient of the Sinuva sinus implant AND
- Physician attests that he or she has specialized training in otolaryngology
Quantity limits
- 1 implant for 90 days; no renewal
Billing for Sinuva
Sinuva must be billed as a medical claim.
Questions?
MHCP Provider Call Center 651-431-2700 or 800-366-5411